LHCGR luteinizing hormone/choriogonadotropin receptor
ENSG00000138039 · protein coding · Open Targets profile
Receptor for lutropin-choriogonadotropic hormone (PubMed:11847099). The activity of this receptor is mediated by G proteins which activate adenylate cyclase (PubMed:11847099). .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, Druggable Family
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM, Human Protein Atlas loc
- PROTAC
- Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.9060900211334229 (upper bound 1.1342999935150146). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 95 registry trials, updated in the last three years, of the most advanced drugs against LHCGR (choriogonadotropin alfa, gonadotropin, chorionic, lutropin alfa, menotropins, lh (menotropins)), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Nikolaos P PolyzosDexeus Universitary Hospital · 4 of 4 trials Phase 2+
- Mehri MashayekhiDepartment of Endocrinology and Female Infertility · 1 of 2 trials Phase 2+
- Abdelmaguid RamzyCairo University · 1 of 1 trials Phase 2+
- Alfonso GalderisiAPHP · 1 of 1 trials Phase 2+
- Ana NevesHospital Universitari Dexeus · 1 of 1 trials Phase 2+
- Antonio La MarcaUniversity of Modena and Reggio Emilia · 1 of 1 trials Phase 2+
- BORDES VirginieInstitut de Cancérologie de l'Ouest · 1 of 1 trials Phase 2+
- Bradley S HurstWake Forest University Health Sciences · 1 of 1 trials Phase 2+
- Cesar Lizan TudelaDepartment of Obstetrics and Gynaecology, Hospital Clínico Universitario de Valencia · 1 of 1 trials Phase 2+
- Chris DeibertUniversity of Nebraska · 1 of 1 trials Phase 2+
- Christophe BlockeelUZ Brussels · 1 of 1 trials Phase 2+
- Eman OmranCairo University · 1 of 1 trials Phase 2+
- Ercan BastuOwner · 1 of 1 trials Phase 2+
- Haiming XiaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 of 1 trials Phase 2+
- Helena TinkanenTampere University Hospital · 1 of 1 trials Phase 2+
Registry trials of choriogonadotropin alfa, gonadotropin, chorionic, lutropin alfa, menotropins, lh (menotropins) updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 78 of 82 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 13 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
46 trials of drugs against LHCGR were stopped early; 10 give no reason
Terminated, withdrawn and suspended interventional trials of choriogonadotropin alfa, gonadotropin, chorionic, lutropin alfa, menotropins, lh (menotropins), newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 46.
- terminated · 2026-03-24 · Masonic Cancer Center, University of Minnesota · matched by the registry's drug synonyms“Sponsor terminated financial support”
- terminated · 2025-02-07 · Reproductive Medicine Associates of New Jersey · matched by the registry's drug synonyms“recruitment issues”
- terminated · 2024-08-22 · Tampere University Hospital · matched by the registry's drug synonyms“High cancellation rate in LH test group in interim analysis”
- terminated · 2024-06-17 · Organon and Co · matched by the registry's drug synonymsNo reason given
- terminated · 2024-05-22 · Fundacion Dexeus · matched by the registry's drug synonyms“Having reached the sample size described for the interim analysis and having seen the post-interim results, the sponsor has decided to stop the trial due to futility.”
- terminated · 2024-03-22 · Instituto Valenciano de Infertilidad, IVI VALENCIA · matched by the registry's drug synonyms“under-recruitment”
- withdrawn · 2024-02-28 · CRG UZ Brussel · Lutropin alfa“withdrawn due to practical reasons”
- withdrawn · 2023-01-09 · Ferring Pharmaceuticals · matched by the registry's drug synonyms“Based on company decision to close the project. No trial participants received any study drug.”
- withdrawn · 2022-11-30 · Assiut University · Menotropins“no women were recruited”
- terminated · 2022-08-11 · IVI Madrid · matched by the registry's drug synonymsNo reason given
- withdrawn · 2022-02-03 · Organon and Co · matched by the registry's drug synonymsNo reason given
- terminated · 2022-01-28 · Reproductive Medicine Associates of New Jersey · matched by the registry's drug synonyms“recruitment issues”
- withdrawn · 2022-01-11 · Reproductive & Genetic Hospital of CITIC-Xiangya · matched by the registry's drug synonyms“Entry criteria were changed, investigator have registrated a new trials.”
- terminated · 2021-05-10 · Universitaire Ziekenhuizen KU Leuven · matched by the registry's drug synonyms“Due to the worldwide Covid-19 pandemic, all Belgian fertility clinics stopped offering IVF as of March 13th 2020. We had to stop recruitment and follow-up of study subjects. We therefore adjusted our primary outcome to time to ongoing pregnancy.”
- terminated · 2021-03-30 · National and Kapodistrian University of Athens · matched by the registry's drug synonyms“Inability for further recruitment, change of position of the principal investigator, COVID-19 pandemic”
- terminated · 2021-01-25 · Fox Chase Cancer Center · matched by the registry's drug synonyms“Unable to recruit volunteers”
- terminated · 2020-02-13 · Celldex Therapeutics · matched by the registry's drug synonyms“Portfolio prioritization due to slow enrollment”
- withdrawn · 2019-12-18 · University of Washington · matched by the registry's drug synonyms“No funding was obtained for this study.”
- terminated · 2019-03-08 · Mount Sinai Hospital, Canada · matched by the registry's drug synonyms“small number of patients got recruited”
- terminated · 2018-11-21 · UConn Health · matched by the registry's drug synonyms“Difficult to recruit patients”
- terminated · 2018-09-14 · St. Olavs Hospital · matched by the registry's drug synonyms“principal investigator left for another job, project leader retired”
- terminated · 2018-08-07 · University Reproductive Associates · matched by the registry's drug synonyms“Drug no longer available by manufacturer”
- withdrawn · 2018-07-19 · University of Virginia · matched by the registry's drug synonyms“The study team decided not to pursue this study.”
- terminated · 2018-03-02 · Instituto de Investigacion Sanitaria La Fe · matched by the registry's drug synonyms“UNDER RECRUITMENT”
- withdrawn · 2017-05-10 · Mohamed Sayed Abdelhafez · matched by the registry's drug synonymsNo reason given
Paediatric incentives and obligations for LHCGR's drugs
For choriogonadotropin alfa, gonadotropin, chorionic, lutropin alfa, menotropins, lh (menotropins): what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · LHCGR is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names choriogonadotropin alfa, gonadotropin, chorionic, lutropin alfa, menotropins, lh (menotropins)Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names choriogonadotropin alfa, gonadotropin, chorionic, lutropin alfa, menotropins, lh (menotropins)Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Pergoveris: authorised since 25 Jun 2007; Ovitrelle: authorised since 2 Feb 2001; Luveris: authorised since 29 Nov 2000Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of choriogonadotropin alfa, gonadotropin, chorionic, lutropin alfa, menotropins, lh (menotropins)Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 32 interventional studies of choriogonadotropin alfa, gonadotropin, chorionic, lutropin alfa, menotropins, lh (menotropins) include patients under 18; 7 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 5 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.